+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07213778

Evaluating REGN7508 Compared to Acetylsalicylic Acid for Preventing Venous Thromboembolism After Elective Total Knee Replacement Surgery

Led by Regeneron Pharmaceuticals · Updated on 2026-10-22

2000

Participants Needed

51

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating REGN7508, an experimental drug, compared to Acetylsalicylic Acid ASA to prevent symptomatic Venous Thromboembolism VTE and related conditions after elective, unilateral total knee replacement surgery in adults. This Phase 3 study aims to understand the drugs effectiveness and safety, including potential side effects and immune responses. Participants will be randomly assigned to receive either REGN7508 with a placebo or ASA with a placebo, following the study protocol. The study uses a double-blinded, parallel design where treatments are administered according to protocol after surgery. Monitoring includes tracking drug levels in the blood and checking for antibodies against REGN7508. During the study, participants will undergo assessments for symptomatic VTE, deep vein thrombosis, pulmonary embolism, bleeding events, and adverse reactions up to 90 days after surgery. The primary measurement is the incidence of symptomatic VTE or death within 30 days. Researchers will also collect safety and drug concentration data to evaluate the drugs effects comprehensively throughout the follow-up period.

CONDITIONS

Brief Title

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here